The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer.
|Articles|April 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
Updated Varian Brachytherapy Applicator Receives Clearance
Updated Varian Brachytherapy Applicator Receives Clearance
Advertisement
PALO ALTO, CaliforniaFDA has granted Varian Medical Systems 510K clearance to market its Esophagus Bougie Set, a brachytherapy applicator designed specifically for intraluminal treatment of esophageal cancer. According to Varian, the new technology allows optimal positioning of the applicator set in reference to the tissue being treated and can be used with Varian's full range of VariSoruce and GammaMed HDR afterloaders.
Articles in this issue
over 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerover 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerover 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerover 19 years ago
Phase III Trial of Prostvac-VF Is Launchedover 19 years ago
Electronic System Reminds Patients to Schedule Examsover 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedover 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caover 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellAdvertisement
Related to this article
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
4
AI Foundation Models & Molecular Biomarkers in Breast Cancer
5